Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple myeloma patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly...

Descripción completa

Detalles Bibliográficos
Autores principales: Reeder, Craig B., Reece, Donna E., Kukreti, Vishal, Chen, Christine, Trudel, Suzanne, Hentz, Joseph, Noble, Brie, Pirooz, Nicholas A., Spong, Jacy E., Piza, Jesus G., Zepeda, Victor H. Jimenez, Mikhael, Joseph R., Leis, Jose F., Bergsagel, P. Leif, Fonseca, Rafael, Stewart, A. Keith
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/
https://www.ncbi.nlm.nih.gov/pubmed/19225538
http://dx.doi.org/10.1038/leu.2009.26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711213/
https://www.ncbi.nlm.nih.gov/pubmed/19225538
http://dx.doi.org/10.1038/leu.2009.26

Ejemplares similares